Nagasree Chakka

This inventor holds 10 USPTO granted patents and 4 published patent applications, plus 4 CIPO patents and 10 EPO patents. Top assignees: Amgen Inc., Teijin Pharma Limited. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nagasree Chakka. Retrieved from https://idiyas.com/inventor/nagasree-chakka-cbkoxm03

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10 (Patent Applications = 4)

% Patents Active = 80.0

CIPO Patents = 4

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 10.6

ph-index = 2

Forward Citations = 43(Granted Patents)

Company Filing History:

Teijin Pharma Limited

patents

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12759982 - Aryl or heteroaryl derivative (2026-10-13),

2. 12492185 - Benzimidazole derivatives and their uses (2025-12-09),

3. 11332459 - Benzimidazole derivatives and their uses (2022-05-17),

4. 9663508 - Biaryl acyl-sulfonamide compounds as sodium channel inhibitors (2017-05-30),

5. 9505749 - Quinazolinone compounds and derivatives thereof (2016-11-29),

6. 9365522 - Pyrazole amide derivative (2016-06-14),

7. 9346798 - Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors (2016-05-24),

8. 9340549 - Oxazolidinone compounds and derivatives thereof (2016-05-17),

9. 9334269 - Carboxamides as inhibitors of voltage-gated sodium channels (2016-05-10),

10. 9012443 - Bicyclic aryl and heteroaryl sodium channel inhibitors (2015-04-21),

Title: The Innovative Genius of Nagasree Chakka

Introduction

Nagasree Chakka, an accomplished inventor located in Lexington, MA, is recognized for his significant contributions to the field of pharmaceuticals, with a remarkable portfolio of eight patents. His work primarily focuses on developing innovative compounds that have the potential to transform treatment approaches for various medical conditions.

Latest Patents

Chakka’s recent patents highlight his dedication to advancing medical science. One such invention is the development of benzimidazole derivatives and their uses, which relates to inhibitors of the Transient Receptor Potential Channel 6 (TRPC6) protein activity. This patent includes a compound of formula (I) or a pharmaceutically acceptable salt, alongside methods for manufacturing these compounds and their therapeutic applications.

Another noteworthy patent involves biaryl acyl-sulfonamide compounds as sodium channel inhibitors. This invention provides compounds of Formula (Ia) and their pharmaceutically acceptable salts. These compounds are specifically tailored to inhibit voltage-gated sodium channels, particularly Nav 1.7, making them instrumental in treating pain disorders.

Career Highlights

Throughout his career, Nagasree Chakka has made significant strides while working with esteemed organizations such as Amgen Inc. and Teijin Pharma Limited. His expertise in pharmaceutical sciences and dedication to innovation has allowed him to make substantial contributions to various research initiatives.

Collaborations

Chakka’s accomplishments have been further enhanced through collaborations with notable individuals, including Howard Bregman and Erin F. DiMauro. These partnerships highlight the synergy of ideas and expertise that contribute to the success of innovative projects in the pharmaceutical industry.

Conclusion

Nagasree Chakka stands as a testament to the power of innovation in the field of pharmaceuticals. With a strong focus on developing compounds that address significant health challenges, his work is paving the way for future advancements. As he continues to contribute to the scientific community, his future inventions promise to benefit many in need of effective treatments.

Profile summary based on public USPTO records.